Loading
Trilaciclib is given as an infusion just before chemotherapy for small cell lung cancer to put the bone marrow's stem cells briefly to sleep, so fewer are killed and patients need fewer transfusions and growth factor injections.
G1 Therapeutics developed trilaciclib as a myeloprotectant rather than an anticancer drug. In three randomised trials in extensive-stage small cell lung cancer it cut the duration and incidence of severe neutropenia, red cell transfusions and growth factor use without reducing tumour responses, because small cell lung cancer lacks functional retinoblastoma protein and is not paused by CDK4/6 inhibition. The FDA approved it in February 2021 to decrease chemotherapy-induced myelosuppression in adults receiving platinum with etoposide or topotecan for extensive-stage small cell lung cancer. A trial in triple-negative breast cancer did not confirm a survival advantage, and Pharmacosmos acquired the drug in 2024.
A short-acting CDK4/6 inhibitor that pauses haematopoietic stem and progenitor cells in G1 for the hours chemotherapy is present, so the cytotoxic drugs kill fewer of them. Connects to CDK4/6.
1.Trilaciclib slips into a pocket on CDK4/6.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2021 | To decrease chemotherapy-induced myelosuppression in adults receiving platinum-etoposide or topotecan for extensive-stage small cell lung cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Trilaciclib" OR ABSTRACT:"Trilaciclib" OR TITLE:"Cosela" OR ABSTRACT:"Cosela" OR TITLE:"G1T28" OR ABSTRACT:"G1T28") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Trilaciclib, not a curated reading list.
Shares Etoposide and the tag chembl-universe.
Shares Etoposide and the tag chembl-universe.
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
Shares G1 Therapeutics, CDK4/6, Small-molecule kinase inhibitors.
Shares the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib, Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C.
Shares Topotecan, Etoposide, Small-cell lung cancer.